PAINREFORM Business Summary

PRF Technologies Ltd. (formerly PainReform Ltd.) operates as a diversified innovation platform following a strategic 2026 rebranding to reflect its expansion into specialty pharmaceuticals and AI-driven energy analytics. The company generates revenue through a dual-track model: a Software-as-a-Service (SaaS) stream via its DeepSolar unit, which provides predictive analytics and technical due diligence for utility-scale solar assets, and a clinical-stage pharmaceutical pipeline focused on the reformulation of established therapeutics. Primary business segments include its legacy post-operative pain program (PRF-110), a majority-owned ophthalmic division (LayerBio) developing sustained-release ocular therapies like OcuRing-K, and the DeepSolar renewable energy platform. PRF Technologies competes directly with specialty pharmaceutical firms such as Pacira BioSciences, Durect Corporation, and Heron Therapeutics, while its energy analytics arm faces competition from industrial AI providers; the company distinguishes itself by leveraging proprietary drug-delivery technology alongside machine-learning assets to mitigate the high-risk profile of single-asset biotech development. The leadership team is anchored by Executive Chairman and Interim CEO Dr. Ehud Geller, a veteran venture capitalist and Managing Partner of Medica Venture Partners with extensive experience in life sciences. Key executives include Chief Technology Officer and Director Dr. Eli Hazum, formerly a partner at Medica and a senior scientist at Glaxo, Interim CFO Eyal Broder, and COO Sigal Aviel. The company was originally founded in 2007 by a scientific team including Dr. Eli Bar, Prof. D. Shmuel, and Prof. Yechezkel Sidi, utilizing technology licensed from the Hadassah Medical Center. Notable institutional presence and strategic backing have historically included Medica Venture Partners, Blade Ranger Ltd., and L.I.A. Pure Capital Ltd., reflecting a board composition that blends deep pharmaceutical R&D expertise with emerging technology commercialization pedigree.